RxDoctor Payments Data

Lissa Sugeng, MD

Cardiovascular Disease · New Haven, CTNPI 1306909825

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,215 of the $21,109 with a category attached, or 67.3%. Siemens Medical Solutions USA, Inc. accounts for 83.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $11,914 and has fallen 93.5% since, to $778 in 2025. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,109in general payments, 2019–2025

Across 44 payments — averaging $479.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$18K
  • Canon Medical Systems USA, Inc.$3K
  • Abbott$317
  • Medtronic$269
  • Lantheus Medical Imaging, Inc.$174
  • Abiomed$110
  • plus $191 from 4 others
$88,446in research payments, 2019–2025

Across 8 payments — averaging $11,056 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Siemens Medical Solutions USA, Inc.$88K

What the payments were for

  • Speaking & faculty fees$14,21567%
  • Travel & lodging$5,60227%
  • Food & beverage$1,2916%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,109 in reported general payments places this provider in the 90th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$62,089
Medicare patients
747
Services billed
1,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spironolactone11$62

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →